Another NSCLC study found a significantly shorter median PFS of 6.3 months in patients with detectable pEGFR, compared with 10.1 months for those with undetectable pEGFR after two-month EGFR-TKI treatment [15]. Here, EGFR is linked to non-small cell lung carcinoma.